TheEdgeResearch
Home / Stocks / HUMDF

Hua Medicine (Shanghai) Ltd. (HUMDF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.30 ▲ +0.00%
Market Cap
$303.2M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.80
52-Wk Range
0.2935-0.5
CEO
Li Chen
Country
CN
Currency
USD

Hua Medicine (Shanghai) Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $0.30, up 0.00% on the session, giving a market capitalisation of $303.2M. On trailing twelve-month figures it carries a trailing P/E of -16.82, a net margin of -16.5%. Its beta of 0.80 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-16.82
Price / Sales
2.66
Price / Book
1.72
EV / EBITDA
-12.89
Gross margin
60.6%
Operating margin
-16.2%
Net margin
-16.5%
Return on equity
—
Debt / equity
0.36
Current ratio
3.34
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
328
IPO date
2021-03-15
Headquarters
Shanghai, SH, CN
About Hua Medicine (Shanghai) Ltd.

Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.

More research on HUMDF
HUMDF technical analysis HUMDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →